Log in to save to my catalogue

Potential for Maternally Administered Vaccine for Infant Group B Streptococcus

Potential for Maternally Administered Vaccine for Infant Group B Streptococcus

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2840248994

Potential for Maternally Administered Vaccine for Infant Group B Streptococcus

About this item

Full title

Potential for Maternally Administered Vaccine for Infant Group B Streptococcus

Publisher

United States: Massachusetts Medical Society

Journal title

The New England journal of medicine, 2023-07, Vol.389 (3), p.215-227

Language

English

Formats

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

Natural history studies have correlated serotype-specific anti-capsular polysaccharide (CPS) IgG in newborns with a reduced risk of group B streptococcal disease. A hexavalent CPS-cross-reactive material 197 glycoconjugate vaccine (GBS6) is being developed as a maternal vaccine to prevent invasive group B streptococcus in young infants.
In an on...

Alternative Titles

Full title

Potential for Maternally Administered Vaccine for Infant Group B Streptococcus

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2840248994

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2840248994

Other Identifiers

ISSN

0028-4793,1533-4406

E-ISSN

1533-4406

DOI

10.1056/NEJMoa2116045

How to access this item